Data from 368 patients with AOD or AOA recruited in The European Organisation for Research and Treatment of Cancer ( EORTC ) trial 26951 on adjuvant PCV ( Procarbazine , CCNU , Vincristine ) chemotherapy in anaplastic oligodendroglial tumours were used to develop multifactor models to predict progression free survival ( PFS ) and overall survival ( OS ) .
